Skip to content
AiSeekAiSeek
Sign in
NewMarketsReported 2026-10-09 20:30

Outlook Therapeutics Names Greg DiPasquale as Chief Commercial Officer

Outlook Therapeutics, Inc. has appointed Greg DiPasquale as Chief Commercial Officer, leading all commercial functions for the upcoming launch of LYTENAVA in the U.S.

Why it matters. The appointment affects the commercial readiness of LYTENAVA, the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD, impacting patient access and market position.

01

Who it touches

  1. 1Outlook Therapeutics, Inc.
  2. regulatory exposure →Fact
    2regulatory approvalsPolicy
02

Evidence

  • GGlobeNewswire public company newsCompany2026-10-09 20:30
    These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals
    View source